Breakthrough Treatments Offer New Hope for Age-Related Macular Degeneration

Revolutionary treatments are giving people with advanced age-related macular degeneration (AMD) their sight back. Two groundbreaking approaches—stem cell transplants and wireless retinal implants—are showing remarkable success in restoring functional vision to patients who had lost hope of ever seeing clearly again.

How Do These New Treatments Actually Work?

The first breakthrough involves surgically removing abnormal blood vessels from the eye and replacing damaged retinal cells with stem cell-derived replacements. In a clinical study of 10 patients with wet AMD, researchers from Third Military Medical University Southwest Hospital in China found that complete removal of blood vessel patches followed by stem cell transplantation led to improved retinal structure and stable or improved vision over 12 months.

The second innovation is the PRIMA device—a tiny wireless chip implanted in the back of the eye that works with high-tech glasses. In a Stanford Medicine-led trial involving 38 patients, this prosthetic system restored enough vision for people to read books and subway signs. The 2-by-2-millimeter chip receives infrared light projected from special glasses and converts it into electrical signals that stimulate the retina.

What Results Are Patients Actually Seeing?

The outcomes from both treatments are impressive. With the stem cell approach, patients where blood vessel patches were completely removed experienced retinal repair and vision stability, while those with incomplete removal continued to have bleeding and inflammation.

The PRIMA device showed even more dramatic results. Of the 32 patients who completed the one-year trial, 27 could read again, and 26 demonstrated clinically meaningful improvement in visual acuity. On average, participants improved by 5 lines on a standard eye chart, with one patient improving by 12 lines. With digital enhancements like zoom and contrast adjustment, some participants achieved vision equivalent to 20/42.

"All previous attempts to provide vision with prosthetic devices resulted in basically light sensitivity, not really form vision," said Daniel Palanker, PhD, a professor of ophthalmology at Stanford Medicine and co-senior author of the PRIMA study. "We are the first to provide form vision."

Who Can Benefit From These Treatments?

These treatments target different stages of AMD, which affects over 5 million people globally and is the leading cause of irreversible blindness among the elderly. The conditions these treatments address include:

• Wet AMD patients: Those with advanced blood vessel formation who haven't responded well to standard drug treatments can potentially benefit from the stem cell transplant approach
• Geographic atrophy patients: People with advanced dry AMD who have lost central vision due to photoreceptor damage are candidates for the PRIMA device
• Elderly populations: Both treatments focus on patients over 60 with severe vision loss, typically worse than 20/320 vision

The PRIMA device offers a particularly innovative approach because patients can use their remaining peripheral vision alongside the prosthetic central vision. "The fact that they see simultaneously prosthetic and peripheral vision is important because they can merge and use vision to its fullest," Palanker explained.

While both treatments showed side effects—including eye pressure issues and retinal tears with PRIMA, and inflammation with incomplete stem cell procedures—most complications resolved within two months and none were life-threatening. These breakthrough treatments represent the first real hope for restoring functional vision to people with advanced AMD, moving beyond simple light sensitivity to actual form recognition and reading ability.